With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33527-91-2,Tris[2-(dimethylamino)ethyl]amine,as a common compound, the synthetic route is as follows.
General procedure: The copper complex Cu5-1 was dissolved in water, and an excessive amount of an aqueous solution of saturated sodium tetrafluoroborate (manufactured by Wako Pure Chemical Industries, Ltd.) was added while stirring. A precipitated solid was collected by filtering and a copper complex Cu5-72 was obtained.
33527-91-2 Tris[2-(dimethylamino)ethyl]amine 263094, achiral-nitrogen-ligands compound, is more and more widely used in various.
Reference£º
Patent; FUJIFILM Corporation; Sasaki, Kouitsu; Kawashima, Takashi; Hitomi, Seiichi; Shiraishi, Yasuharu; US10215898; (2019); B2;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis